EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey

Thomas Santo iD, Chrianna Bharat iD, Craig Rodgers, Mary Harrod iD, Sophia Taylor iD, Emma Zahra iD, Rachel Sutherland iD, Amy Peacock iD, Jason Grebely iD, Matthew Hickman iD, Michael Farrell, Louisa Degenhardt iD

Drug and Alcohol Review · 2026

DOI: 10.1111/dar.70132 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, 2026. Verfasst von Thomas Santo und 11 weiteren Autor:innen. Beteiligte Einrichtung: National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Opiate Substitution Treatment, Harm Reduction, Analgesics, Opioid. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, Australian Government Department of Health, National Health & Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Opioid agonist treatment (OAT) is one of the most effective treatments for opioid dependence, but there can be barriers to accessing treatment. This study examined characteristics associated with OAT engagement—never, previous or current—among people with opioid dependence in NSW, Australia, following recent reforms to OAT access.

Methods

Between October 2023 and March 2024, people with opioid dependence were recruited from services and community settings across NSW. Participants completed structured interviews on socio‐demographics, mental health disorders, substance use and use of prevention and treatment services. Logistic regression was used to examine associations between participant characteristics and engagement with OAT.

Results

Of 403 participants (mean age 44; 65% male), 77% were currently receiving OAT (60% methadone, 11% sublingual buprenorphine and 27% long‐acting injectable buprenorphine), 13% previously and 9% never. Differences between OAT status groups included those currently receiving OAT reporting lower rates of homelessness and extra‐medical opioid use, and greater group therapy engagement and past‐year receipt of naloxone kits compared to those previously and never receiving OAT. Past‐month daily injecting drug use was higher among those previously and never receiving OAT; those previously receiving OAT also reported the highest rate of past‐year supervised injecting facility use and overdoses in the past 6 months. Discussion and Conclusions Those not receiving OAT reported greater social instability, recent injecting drug use and drug‐related harm. Variation in harm reduction service use suggests tailored strategies are needed to reach those outside OAT . These findings highlight the need for integrated, diverse strategies to address dependence‐related harms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersOpiate Substitution TreatmentHarm ReductionAnalgesics, OpioidHumansNew South WalesFemaleMaleAdultBuprenorphineMethadoneMiddle AgedSurveys and Questionnaires

Stichwörter der Autor:innen

incarcerationmental disordersopioid agonist treatmentopioid dependence

Substanzen

BuprenorphineMethadoneAnalgesics, Opioid

Autor:innen und Institutionen

  • National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
  • Alcohol and Drug Services, St Vincent's Hospital, Sydney, Australia.
  • The NSW Users and AIDS Association, Sydney, Australia.
  • School of Psychology, University of Tasmania, Hobart, Australia.
  • The Kirby Institute, UNSW Sydney, Sydney, Australia.
  • Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK.

ORCID-Profile: Thomas Santo, Chrianna Bharat, Mary Harrod, Sophia Taylor, Emma Zahra, Rachel Sutherland, Amy Peacock, Jason Grebely, Matthew Hickman, Louisa Degenhardt

Förderung

  • NIDA NIH HHS
  • Australian Government Department of Health
  • National Health & Medical Research Council
  • Australian National Health and Medical Research Council (NHMRC) Program
  • Department of Health and Aged Care, Australian Government
  • National Drug and Alcohol Research Centre, UNSW Sydney
  • National Health and Medical Research Council
  • Department of Health, Disability and Ageing

Zitieren

APA

Santo, T., Bharat, C., Rodgers, C., Harrod, M., Taylor, S., Zahra, E., Sutherland, R., Peacock, A., Grebely, J., Hickman, M., Farrell, M., & Degenhardt, L. (2026). Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey. Drug and Alcohol Review. https://doi.org/10.1111/dar.70132

Vancouver

Santo T, Bharat C, Rodgers C, Harrod M, Taylor S, Zahra E, et al. Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey. Drug and Alcohol Review. 2026. doi:10.1111/dar.70132

BibTeX
@article{Santo2026,
  author = {Santo, Thomas and Bharat, Chrianna and Rodgers, Craig and Harrod, Mary and Taylor, Sophia and Zahra, Emma and Sutherland, Rachel and Peacock, Amy and Grebely, Jason and Hickman, Matthew and Farrell, Michael and Degenhardt, Louisa},
  title = {Factors Associated With Opioid Agonist Treatment Engagement and Harm Reduction Service Use: Findings From the New South Wales Opioid Dependence Survey},
  journal = {Drug and Alcohol Review},
  year = {2026},
  doi = {10.1111/dar.70132}
}
Kostenlos starten →